Market Closed -
Nasdaq
16:00:00 2024-05-15 EDT
5-day change
1st Jan Change
12.18
USD
+3.05%
-10.51%
+78.59%
This article is reserved for members
Not a member ?
Free registration
Transcript : Y-mAbs Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
05-08
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q1 Revenue $19.9M, vs. Street Est of $22.2M
05-07
MT
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-07
CI
Y-mAbs Therapeutics, Inc. Announces Resignation of Gérard Ber, Ph.D. from the Board of Directors, Effective June 10, 2024
04-29
CI
Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign
03-14
MT
Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024
03-14
CI
Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer
03-14
CI
HC Wainwright Adjusts Price Target on Y-mAbs Therapeutics to $22 From $21, Keeps Buy Rating
03-06
MT
Canaccord Genuity Raises Price Target on Y-mAbs Therapeutics to $26 From $22, Maintains Buy Rating
03-04
MT
BMO Capital Adjusts Y-mAbs Therapeutics Price Target to $26 From $16, Maintains Outperform Rating
03-04
MT
Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors
03-04
CI
Wedbush Raises Y-mAbs Therapeutics' PT to $23 From $18 After Higher-Than-Expected Q4 2023 Danyelza Net Product Revenue, Maintains Outperform Rating
03-04
MT
Transcript : Y-mAbs Therapeutics, Inc., Q4 2023 Earnings Call, Mar 01, 2024
03-01
Y-mAbs Therapeutics Surges 18% in Premarket Activity Following Q4 Results; Reiterates Anticipated Cash Runway into 2027
03-01
MT
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
02-29
CI
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Reports Q4 Revenue $23.4M, vs. Street Est of $21M
02-29
MT
Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024
02-29
CI
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
02-29
CI
HC Wainwright Adjusts Y-mAbs Therapeutics Price Target to $21 From $11, Maintains Buy Rating
02-20
MT
Wedbush Raises Price Target on Y-mAbs Therapeutics to $18 From $12 After Plans for Phase 1 Cancer Drug Study, Keeps Outperform Rating
02-12
MT
Transcript : Y-mAbs Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM
01-10
Kempen Upgrades Y-mAbs Therapeutics to Buy From Neutral, Price Target is $10
12-22
MT
Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) added to NASDAQ Biotechnology Index
12-18
CI
Y-mAbs Therapeutics to Join NASDAQ Biotechnology Index Dec. 18
12-13
MT
Y-mabs Therapeutics Insider Bought Shares Worth $521,294, According to a Recent SEC Filing
11-29
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
More about the company
Last Close Price
12.18
USD
Average target price
21.33
USD
Spread / Average Target
+75.15%
Consensus
1st Jan change
Capi.
+78.59% 534M +7.52% 113B +11.38% 106B -12.64% 22.22B +0.20% 22.27B -3.53% 19.43B -37.85% 17.87B -8.58% 17.24B +37.41% 12.52B -23.95% 8.34B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**